The antidepressant effect of ketamine [116,117] is seemingly in agreement with the glutamatergic hypothesis of depression [118], postulating that NMDAR antagonism increases the synthesis of the brain-derived neurotrophic factor (BDNF) [119,120]. The gene discussed is BDNF; the disease is depressive symptom measurement.